Navigation Links
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
Date:7/16/2008

SEATTLE, July 16 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has initiated a Phase 2 trial of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of prostate cancer, in men with localized prostate cancer who are scheduled to undergo a radical prostatectomy. The single-center trial called NeoACT (NEOadjuvant Active Cellular immunoTherapy), or P07-1, which is being conducted at UCSF Helen Diller Family Comprehensive Cancer Center, has begun enrolling approximately 40 patients. NeoACT is the first of two new Phase 2 trials of PROVENGE being initiated this year.

Each patient will receive a complete course of active treatment over a one-month period beginning six to seven weeks prior to the patient's radical prostatectomy. The course of treatment will consist of three infusions of PROVENGE-two weeks apart. Multiple safety and efficacy endpoints will be evaluated including the immune response in the prostatectomy specimens and in the peripheral blood. Following radical prostatectomy, patients will be randomized to receive either a booster of PROVENGE or no booster. Patients interested in additional information about this trial may visit http://www.clinicaltrials.gov and use the search term "NeoACT."

"I am pleased to help lead the NeoACT clinical trial, given the therapeutic potential of immunotherapy for prostate cancer," stated Lawrence Fong, M.D., principal investigator of the NeoACT trial and associate professor of medicine at UCSF Helen Diller Family Comprehensive Cancer Center. "This study will provide a unique opportunity to examine the immune response to PROVENGE in
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
3. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
9. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
10. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... N.Y., March 30, 2015  Uroplasty, Inc. (NASDAQ: ... ) shareholders have voted at the special meeting ... the previously announced agreement and plan of merger ... pleased with the outcome of today,s special meetings, ... groups for approving the merger agreement," said ...
(Date:3/30/2015)... , March 30, 2015 Perrigo Company plc ... of "Quality Affordable Healthcare Products®," today announced that it ... N.V. ("Omega") in a cash and equity transaction valued ... €1.3 billion in debt. Sellers are Marc Coucke ... of Waterland.    "The combination ...
(Date:3/30/2015)... -- A team of Chinese and US scientists has ... that plays a critical role in thrombosis, or blood ... features, which challenge the conventional concepts of drug action ... door for future drug discovery. In a ... the researchers at Shanghai Institute of Materia Medica ...
Breaking Medicine Technology:Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 2Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 4Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 5New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 2New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 3New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 4New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 5New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 6
(Date:3/31/2015)... March 31, 2015 Effective April, 1 ... be moving his practice with North Texas Obstetrics & ... pursue his progressive approach to women’s healthcare. With 17 ... Dr. Eisenberg ensures this move will not interrupt the ... resources to open his practice to new patients. , ...
(Date:3/31/2015)... If you or someone you love ... from Irritable Bowel Syndrome (IBS), you will want to ... Lifetime Television® at 7:30am EDT/PDT on either Wednesday, April ... an informative health segment featuring interviews with Board Certified ... MD and Medical Scientist Victoria Jaison, PhD. To learn ...
(Date:3/31/2015)... March 31, 2015 First Choice ... emergency rooms in the United States, announced that it ... , “I am pleased to announce that we are ... in Haslet,” said Dr. James M. Muzzarelli, Executive Medical ... Choice Emergency Room is revolutionizing the delivery of emergency ...
(Date:3/31/2015)... With nationwide predictions of major floods due ... the pineapple express, the OPP is urging its insureds ... FEMA , "Protecting Your Business" 09/23/2014, provides alarming statistics ... your business. , Here are 3 statistics that every ... of small businesses never reopen their doors after a ...
(Date:3/30/2015)... Fl (PRWEB) March 31, 2015 AlignLife ... Hamtaee has recently opened his AlignLife clinic. As part ... offering of chiropractic, rehabilitation and nutritional consulting for all ... AlignLife is based on the expertise and compassion of ... pass a rigorous evaluation process and an extensive training ...
Breaking Medicine News(10 mins):Health News:Plano OBGYN Dennis Eisenberg, MD Joins North Texas Obstetrics & Gynecology Associates in Plano, Texas 2Health News:EnteraGam® to Be Featured on The Balancing Act® Airing on Lifetime Television® 2Health News:EnteraGam® to Be Featured on The Balancing Act® Airing on Lifetime Television® 3Health News:EnteraGam® to Be Featured on The Balancing Act® Airing on Lifetime Television® 4Health News:First Choice Emergency Room to Open New Facility in Haslet, Texas 2Health News:3 Statistics Every Business Owner Should Know About Flood Waters and Flood Insurance, from the Optometric Protector Plan® 2
... Kirsten Vangsness, Nanny 911,s Nanny Stella, ,Notes From the Underbelly, star ... the industry,s most fun ... fundraiser, LOS ANGELES, March ... 5th from 1pm - 4pm at the Loews Santa,Monica Hotel. The event will ...
... WetFeet Co-founder and CEO Gary Alpert to Lead Company,s Partnership ... ... Caring.com is pleased to,announce the arrival of Gary Alpert ... be responsible for the company,s,partnership and content licensing programs., ...
... Md., March 26 An annual analysis,to help ... that need,quality improvement now includes important information such ... mental illness and the number,of specialist doctors., ... factors" - are part,of the 2007 State Snapshots ...
... Researchers Strive to Help Caregivers of Dementia Patients Through ... T ) today,announced a $49,993 grant to the ... funding will be used to examine a,computer-integrated system for ... million adults in the nation provide care to someone,suffering ...
... Over 700 Frontline Clinicians Committed to ... March 26 The American Headache ... Medicine (AOAAM), American,Society of Pain Educators ... (IMDHA), National Fibromyalgia Research,Association (NFRA), National ...
... Rally for the Concerns of General Dentists and Their ... General Dentistry,s,(AGD) second annual advocacy conference, A Great Dentist ... 60 AGD constituent,leaders and member general dentists from 30 ... applied these sophisticated skills to more,than 100 Congressional offices ...
Cached Medicine News:Health News:Celebrities From All Walks of Life Put Their Best Foot Forward for the Fourth Annual Open Toe Shoe Party 2Health News:Caring.com Adds Vice President of Business Development 2Health News:AHRQ's 2007 State Snapshots Provide Broader Portraits of State-By-State Health Care Performance 2Health News:AHRQ's 2007 State Snapshots Provide Broader Portraits of State-By-State Health Care Performance 3Health News:AT&T Announces Grant to Center on Aging-University of Miami Miller School of Medicine 2Health News:AT&T Announces Grant to Center on Aging-University of Miami Miller School of Medicine 3Health News:National Pain Organizations Converge at PAINWeek(TM) 2008 2Health News:National Pain Organizations Converge at PAINWeek(TM) 2008 3Health News:AGD Advocacy Conference Connects General Dentists with Congress 2
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: